Skip to main content
SpringerLink
Log in

Triptorelin embonate (6-month formulation): a guide to its use in advanced prostate cancer

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1

References

  1. Keating GM. Triptorelin embonate (6-month formulation). Drugs 2010: 70(3): 347–53

    Article  PubMed  CAS  Google Scholar 

  2. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008 Jan; 53(1): 68–80

    Article  PubMed  Google Scholar 

  3. Anderson J, Abrahamsson P-A, Crawford D, et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 2008 Jun; 101(12): 1497–501

    Article  PubMed  Google Scholar 

  4. Heyns CF. Triptorelin in the treatment of prostate cancer: clinical efficacy and tolerability. Am J Cancer 2005; 4(3): 169–83

    Article  CAS  Google Scholar 

  5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™: prostate cancer v.2.2009 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf [Accessed 2010 Apr 27]

  6. Lundström EA, Rencken RK, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multi-centre, phase III study. Clin Drug Invest 2009; 29(12): 757–65

    Article  Google Scholar 

  7. Pamorelin LA (triptorelin) 22.5 mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics. London: European Medicines Agency, 2009

    Google Scholar 

  8. Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982 Jun; 54(6): 1169–73

    Article  PubMed  CAS  Google Scholar 

  9. Debiopharm Group. Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer [media release]. Available from URL: http://www.debiopharm.com [Accessed 2010 Apr 27]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Triptorelin embonate (6-month formulation): a guide to its use in advanced prostate cancer. Drugs Ther. Perspect 26, 5–7 (2010). https://doi.org/10.2165/11205220-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205220-000000000-00000

Search

Navigation